Development of a liquid chromatography-mass spectrometry method for monitoring the angiotensin-converting enzyme inhibitor lisinopril in serum

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

Volumn 783, Issue 2, 2003, Pages 425-432

  Tsakalof, Andreas ^a   Bairachtari, Kyriaki ^a   Georgarakis, Manolis ^b  

^a The Ormylia Foundation   (Greece)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Lisinopril

Indexed keywords

AMMONIUM COMPOUNDS; EXTRACTION; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PH EFFECTS;

ELECTROSPRAY INTERFACES;

ENZYME INHIBITION;

ACETONITRILE; AMMONIUM FORMATE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LISINOPRIL; METHANOL;

ARTICLE; DEVICE; DRUG MONITORING; EFFLUENT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MASS SPECTROMETRY; PH; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SOLID PHASE EXTRACTION; TEMPERATURE; BLOOD; CALIBRATION; ELECTROSPRAY MASS SPECTROMETRY; METHODOLOGY; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; ULTRAVIOLET SPECTROPHOTOMETRY; VALIDATION STUDY;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALIBRATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMANS; LISINOPRIL; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; SPECTROPHOTOMETRY, ULTRAVIOLET;

EID: 0037437670     PISSN: 15700232     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1570-0232(02)00704-3     Document Type: Article

References (15)

1. Parfitt K. Martinedale - The Complete Drug Reference. 32nd Ed.:1999;898 Pharmaceutical Press.
2. British Pharmacopoeia. 1998;799 Her Majesty's Stationary Office, London.
3. Ip D.P., Demarco J.D., Brooks M.A. Analytical Profiles of Drug Substances. Vol. 21:1992;Academic Press, New York.
4. M. Hichens, E.L. Hand, W.S. Mulcahy, Ligand Quartery 4 (1981).
5. Sun Y., Mendelsohn F.A.O. J. Cardiovasc. Pharmacol. 18:1991;478.
6. Leis H.J., Fauler G., Raspotnig G., Windischhofer W. Rapid Commun. Mass Spectrom. 12:1998;1591.
7. Leis H.J., Fauler G., Raspotnig G., Windischhofer W. Rapid Commun. Mass Spectrom. 13:1999;650.
8. Wong Y.C., Charles B.G. J. Chromatogr. B. 673:1995;306.
9. The Merck Index. 12th Ed.: 1996;Merck, Whitehouse Station, NJ.
10. Lancaster S.G., Todd P.A. Drugs. 35:1988;646.
11. Kocijan A., Granek R., Kocjan D., Zupanèiè-Kralj L. J. Chromatogr. B. 755:2001;229.
12. Qin X.Z., DeMarco J., Ip D.P. J. Chromatogr. 707:1995;245.
13. Analytical Methods Validation for Human Studies. US Department of Health and Human Services Food and Drug Administration, CDER, December 1998.
14. Snyder L.R., Glajach J.L., Kirkland J.J. Practical HPLC Method Development. 1988;Wiley.
15. M. Georgarakis, A. Tsakalof, F. Zougrou, G. Kontopoulos, I. Tsiptsios, Arzneim. Forsch. Drug Res. (in press).